New treatment modalities in Alzheimer's disease

doi:10.12998/wjcc.v7.i14.1764

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6935)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

632

WORD

317

HTML

4589

Tables (1-2)

183

Sum=5721

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

501

Download

713

Sum=1214

Jul 26, 2019 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jul 26, 2019; 7(14): 1764-1774
Published online Jul 26, 2019. doi: 10.12998/wjcc.v7.i14.1764

Table 1 Potential treatments related to BACE1 and p-tau undergoing clinical trials

Target	Drug	Study phase	Expected completion date	Results
BACE1	Lanabecestat	2	September 2019
	JNJ-54861911	2	October 2022
	Elenbecestat	3	December 2020
	Verubecestat	3	March 2021
	LY450139	3	Completed April 2011	Not effective
P-tau	IONIS-MAPTRx	1, 2	February 2020
	JNJ-63733657	1	February 2019
	RO7105705	2	September 2022
	ABBV-8E12	2	June 2021
	AADvac 1	2	June 2019
	BIIB-092	2	September 2020
	BIIB-080	1	February 2020
	TPI-287	1	Completed May 2017
	TRx0237	3	February 2019
	LY3303560	1	June 2019
	MTAU9937A	2	(-) Continuing
	E2814	1	(-) Continuing

BACE1: β-site amyloid precursor protein cleaving enzyme 1; p-tau: Hyperphosphorylated tau peptide.

Citation: Koseoglu E. New treatment modalities in Alzheimer's disease. World J Clin Cases 2019; 7(14): 1764-1774
URL: https://www.wjgnet.com/2307-8960/full/v7/i14/1764.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i14.1764